Verslagen

Samenvatting van de aanvraag

Samenvatting
Dit item is dichtgeklapt
Dit item is opengeklapt

RESEARCH QUESTION

Does adding a virtual reality self-management stress-reduction tool (VRelax) to treatment as usual (TAU) reduce psychiatric symptoms, medication use, improve psychosocial functioning and reduce costs in patients with anxiety, depressive, bipolar or psychotic disorder when compared to TAU only, and what are the barriers and facilitators for implementation of VRelax in healthcare?

 

HYPOTHESIS

Adding VRelax to TAU reduces psychiatric symptoms, medication use and improves psychosocial functioning at a lower cost than TAU.

 

DESIGN

Multi-center randomized controlled trial.

 

POPULATION

Patients with anxiety, depressive, bipolar or psychotic disorder.

 

INTERVENTION

VRelax: VR 360 degree videos of calm natural environments with interactive stress-reducing elements in addition to TAU. The intervention will be adjusted for the purpose of this study and improved iteratively in collaboration with a user panel consisting of patients and healthcare providers before the trial commences.

TAU: Treatment following national guidelines.

 

OUTCOMES

Primary: psychiatric symptoms

Secondary: medication use, psychosocial functioning, substance use, stress, sleep, costs, physiological outcomes, process evaluations

 

PROCESS EVALUATION

In-depth patient interviews.

 

STATISTICS

185 participants, intention to treat, mixed-effects regression analyses.

Naar boven
Direct naar: InhoudDirect naar: NavigatieDirect naar: Onderkant website